Advances in Gene Therapy (TechVision)

Technology and Market Trends

USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

The objective of this research service is to provide an exhaustive analysis of the current trends in gene therapy. The research service comprises details of technology challenges, market drivers and restraints in addition to the competitive landscape present in the gene therapy market space. The research service analyzes the recent developments in companies with respect to a variety of diseases application areas. A thorough and exhaustive overview of product candidates and the phases of clinical trial development across the United states is provided.

The information in this research service will detail the areas in gene therapy that are experiencing significant growth in the United States, with associated and pertinent advancements around the globe. It will clearly breakdown the key success indicators, that have shown to hold positive outlook for commercialization over the short term future.

Table of Contents

Executive SummaryScopeMethodology Sneak PreviewIntroduction Gene Therapy, Event Timeline, 1997-2014 Gene Therapy, Event Timeline, 1997-2014 Gene Therapy, Event Timeline, 1997-2014 Technology Readiness Level ApproachTechnology AssessmentTechnology Segments Technology Segments (continued)Non viral vectorsNon viral vectors Viral Vectors Viral Vectors (continued) Viral Vectors (continued)Viral Vectors (continued)Viral Vectors (continued)Viral Vectors (continued)Gene Types Impact on ApplicationsIntroductionSegmentation by Disease areaMonogenic DiseaseMonogenic Disease (continued) Monogenic Disease (continued) Monogenic Disease: Product ReservoirMonogenic Disease: Product Reservoir (continued)Monogenic Disease: Product Reservoir (continued)Cancer DiseaseCancer Disease (continued) Cancer Disease: Product ReservoirCancer Disease: Product Reservoir (continued)Cancer Disease: Product Reservoir (continued)Cardiovascular DiseasesCardiovascular Disease (continued) Cardiovascular Disease: Product ReservoirOther DiseasesOther Disease: Product ReservoirOther Disease: Product Reservoir (continued)Gene Therapy Products on the HorizonEmerging disease areasAnalysis of the Industry EnvironmentVenture Capital Funding Assessment Venture Capital Funding Assessment (continued)Role of Big PharmaRole of Big Pharma (continued)Clinical Trials OverviewDriversDrivers ExplainedDrivers Explained (continued) Drivers Explained (continued)Drivers Explained (continued)RestraintsRestraints ExplainedRestraints Explained (continued) Restraints Explained (continued) Restraints Explained (continued) Competitive LandscapeCompany ProfilesCompany ProfileCompany ProfileCompany ProfileCompany ProfileCompany ProfileCompany ProfileCompany ProfileCompany ProfileCompany ProfileCompany ProfileCompany ProfileLegal DisclaimerAppendixGlossaryGlossary (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Keyword1
gene therapy
Keyword2
gene therapy technologies
Keyword3
gene therapy

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 20-Nov-17

Region : North America

Release Date : 17-Nov-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.